Small Molecule Inhibitors for Anaphylaxis Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for anaphylaxis and mast-cell mediated allergic disorders are inadequate in preventing or reducing the severity of allergic reactions, as they often require immediate administration and may not effectively inhibit mast cell degranulation or address underlying biological mechanisms.
Innovation Solution
Development of novel compounds and methods that inhibit mast cell activity, specifically targeting Stat3 and Stat1 proteins to prevent mast cell degranulation, including the use of small molecules that interact with the Stat3 SH2 domain to inhibit cytokine-mediated phosphorylation and nuclear translocation, thereby reducing the risk or severity of allergic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for anaphylaxis are administered, then immediate reaction management is provided, but they fail to prevent or reduce the severity of allergic reactions effectively
Solution Approach 1:
The patent applies preliminary action by administering the compound before exposure to the allergen, allowing the compound to pre-inhibit mast cell degranulation pathways. This preventive administration enables the treatment to be effective before the allergic reaction is triggered, rather than requiring immediate post-exposure intervention.
2Speed
If treatments are administered immediately after allergen exposure, then rapid response is achieved, but prevention of mast cell degranulation is insufficient
Solution Approach 1:
The patent applies preliminary anti-action by using the compound to pre-block the mast cell degranulation pathway before the allergen can trigger the reaction. The compound is administered in advance to establish protective inhibition of the degranulation mechanism, creating a preemptive barrier against the allergic response.
3Ease of operation
If conventional treatments are used, then immediate symptom management is provided, but underlying biological mechanisms are not addressed
Solution Approach 1:
The patent applies the intermediary principle by using a small molecule compound as a mediator that targets specific proteins involved in the mast cell degranulation pathway. The compound acts as an intermediary agent that blocks the signaling cascade from allergen exposure to mast cell activation, addressing the underlying biological mechanism while maintaining ease of administration.
Data Source
AI summary
Embodiments of the invention include methods of preventing and/or reducing the risk or severity of an allergic reaction in an individual. In some embodiments, particular small molecules are employed for prevention and/or reduction in the risk or severity of anaphylaxis. In at least particular cases, the small molecules are inhibitors of STAT3. In some cases, the small molecule comprises N-(1′,2-dihydroxy-1,2′-binaphthalen-4′-yl)-4-methoxybenzenesulfonamide.